Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.37 |
| ▸ | UBE2M | P61081 | 1/20 | 0.37 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.35 |
| ▸ | PNMT | P11086 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15701713 | 0.87 | SMN1; SMN2 (0.40) | TAAR1S1PR1ALDH1A1LMNAMAPT | |
| SCHEMBL9523875 | 0.81 | SIGMAR1 (0.49) | TAAR1S1PR1SIGMAR1 | |
| SCHEMBL14149934 | 0.77 | MAPT (0.47) | TSHRS1PR1SIGMAR1ALDH1A1MAPT | |
| SCHEMBL15701712 | 0.74 | LMNA (0.40) | ALDH1A1LMNAHTT | |
| SCHEMBL15701724 | 0.74 | TAAR1 (0.46) | TAAR1ALDH1A1MAPT | |
| SCHEMBL6872368 | 0.74 | ESR1 (0.45) | ALDH1A1LMNAKDM4E | |
| SCHEMBL8414086 | 0.74 | MAPT (0.49) | TAAR1TSHRALDH1A1LMNAMAPT | |
| SCHEMBL9095640 | 0.74 | S1PR1 (0.44) | TSHRS1PR1SIGMAR1ALDH1A1VCAM1 | |
| SCHEMBL15701710 | 0.73 | TAAR1 (0.43) | TAAR1 | |
| SCHEMBL13503172 | 0.73 | TAAR1 (0.46) | TAAR1ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9346795-B2 | Substituted sulfonamides useful as antiapoptotic Bcl inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-24 | — | — | US | disclosed |
| US-20140135318-A1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135318-A1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BCL2, BAX, BCL2A1 | TAAR1 4847/4885TSHR 4522/4885S1PR1 1142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.